Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE v stent in a porcine coronary artery model

Circulation: Cardiovascular Interventions

Volumn 7, Issue 3, 2014, Pages 330-342

  Otsuka, Fumiyuki ^a   Pacheco, Erica ^a   Perkins, Laura E L ^b   Lane, Jennifer P ^b   Wang, Qing ^b   Kamberi, Marika ^b   Frie, Michael ^c   Wang, Jin ^b   Sakakura, Kenichi ^a   Yahagi, Kazuyuki ^a   Ladich, Elena ^a   Rapoza, Richard J ^b   Kolodgie, Frank D ^a   Virmani, Renu ^a  

^a CVPATH INSTITUTE   (United States)

^b ABBOTT VASCULAR   (United States)

^c American Preclinical Services   (United States)

Author keywords

Coronary disease; Pathology; Stents

Indexed keywords

CHROMIUM DERIVATIVE; EVEROLIMUS; RAPAMYCIN;

ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; ANIMAL; ANIMAL MODEL; BIODEGRADABLE IMPLANT; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; DRUG ELUTING STENT; INCIDENCE; MINIPIG; NEOINTIMA; PATHOLOGY; PIG; RADIOGRAPHY; SCANNING ELECTRON MICROSCOPY; STENT; TIME; TISSUE SCAFFOLD; ULTRASTRUCTURE; VASCULITIS;

ABSORBABLE IMPLANTS; ANIMALS; CHROMIUM ALLOYS; CORONARY ANGIOGRAPHY; CORONARY VESSELS; DRUG-ELUTING STENTS; INCIDENCE; MICROSCOPY, ELECTRON, SCANNING; MODELS, ANIMAL; NEOINTIMA; SIROLIMUS; STENTS; SWINE; SWINE, MINIATURE; TIME FACTORS; TISSUE SCAFFOLDS; VASCULITIS;

EID: 84905817286     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.113.000990     Document Type: Article

References (26)

1. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to frst-generation sirolimus-and paclitaxel-eluting stents. J Am Coll Cardiol. 2011;57:390-398.
2. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314-1322.
3. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascular-ization in the upcoming decade? Eur Heart J. 2012;33:16-25b.
4. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371:899-907.
5. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897-910.
6. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv. 2012;5:620-632.
7. Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ; SPIRIT IV Investigators. Randomized comparison of everolimus-and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011;58:19-25.
8. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E, Finn AV, Kolodgie FD, Virmani R. Pathology of second-generation everolimus-eluting stents versus frst-generation sirolimus-and paclitaxel-eluting stents in humans. Circulation. 2014;129:211-223.
9. tm everolimus-eluting coronary stent system: A preclinical assessment. J Interven Cardiol. 2009;22:S28-S40.
10. Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani R. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv. 2011;4:38-46.
11. Lane J, Perkins L, Sheehy A, Pacheco E, Frie M, Lambert B, Rapoza R, Virmani R. Lumen gain and restoration of pulsatility following implantation of a bioresorbable vascular scaffold in porcine coronary arteries [published online ahead of print May 9, 2014]. JACC Cardiovasc Interv. doi: 10.1016/j.jcin.2013. 11.024.
12. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-274.
13. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent infammation at sites of overlapping siroli-mus-or paclitaxel-eluting stents. Circulation. 2005;112:270-278.
14. Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
15. Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C. Exposure-response relationships for everolimus in de novo kidney transplantation: defning a therapeutic range. Transplantation. 2002;73:920-925.
16. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
17. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-1402.
18. Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110-1121.
19. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-2980.
20. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R. Comparison of infammatory response after implantation of sirolimus-and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009;120:141-9, 1.
21. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5-24.
22. Brown BN, Londono R, Tottey S, Zhang L, Kukla KA, Wolf MT, Daly KA, Reing JE, Badylak SF. Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials. Acta Biomater. 2012;8:978-987.
23. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation. 2002;105:297-303.
24. Naito M, Stirk CM, Smith EB, Thompson WD. Smooth muscle cell outgrowth stimulated by fbrin degradation products. The potential role of fbrin fragment E in restenosis and atherogenesis. Thromb Res. 2000;98:165-174.
25. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
26. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of infammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224-230.